Altered vascular injury responses in mice deficient in protease- activated receptor-1

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 12, 1999, Pages 3014-3024

  Cheung, Wai Man ^a   D'Andrea, Michael R ^a   Andrade Gordon, Patricia ^a   Damiano, Bruce P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cell proliferation; Knockout mouse; Protease activated receptor; Thrombin; Thrombin receptor

Indexed keywords

BROXURIDINE; EVANS BLUE; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CELL DENSITY; CELL PROLIFERATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM LESION; INTIMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0033396454     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.12.3014     Document Type: Article

References (45)

1. Stouffer GA, Schmedtje JF, Gulba D, Huber K, Bode C, Aaron J, Runge MS. Restenosis following percutaneous revascularization: the potential role of thrombin and the thrombin receptor. Ann Hematol. 1996;73: S39-S41.
2. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol. 1995;75: B12-B17.
3. Stadel JM. Thrombin: a versatile protease in restenosis. Fundam Clin Cardiol. 1997;28:161-176.
4. Hatton M, Moar S, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol. 1989;135:499-508.
5. Walz DA, Anderson GF, Ciaglowski RE, Aiken M, Fenton JW II. Thrombin-elicited contractile responses of aortic smooth muscle. Proc Soc Exp Biol Med. 1985;180:518-526.
6. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S, Munz DL, Wiegand V. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol. 1993;21:249-254.
7. Heras M, Chesebro J, Webster M, Mruk J, Grill D, Penny W, Bowie E, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.
8. Abendschein DR, Recchia D, Meng YY, Oltrona L, Wickline SA, Eisenberg PR. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs. J Am Coll Cardiol. 1996;28:1849-1855.
9. Barry WL, Gimple LW, Humphries JE, Powers ER, McCoy KW, Sanders JM, Owens GK, Sarembock IJ. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model: time course and effect of hirudin. Circulation. 1996;94:88-93.
10. Gerdes C, Faber-Steinfeld V, Yalkinoglu O, Wohlfeil S. Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury. Arterioscler Thromb Vasc Biol. 1996;16:1306-1311.
11. Serruys PW, Herman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, Van Dijk R, Van Den Bos AA, Umans VAWM, Fox KA, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
12. Burchenal JEB, Marks DS, Mann JT, Schweiger MJ, Rothman MT, Ganz P, Adelman B, Bittl JA. Effect of direct thrombin inhibition with bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am J Cardiol. 1998;82:511-515.
13. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shin MF, Sujatta M, Bonan R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol. 1996;28:1437-1443.
14. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
15. 2+ mobilization. FEBS Lett. 1991;288:123-128.
16. Muramatsu I, Laniyonu A, Moore GJ, Hollenberg MD. Vascular actions of thrombin receptor peptide. Can J Physiol Pharmacol. 1992;70: 996-1003.
17. Antonaccio MJ, Normandin D, Serafino R, Moreland S. Effects of thrombin and thrombin receptor activating peptides on rat aortic vascular smooth muscle. J Pharmacol Exp Ther. 1993;266:125-132.
18. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993;22:609-616.
19. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
20. Dabbagh K, Laurent GJ, McAnulty RJ, Chambers RC. Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. Thromb Haemost. 1998;79:405-409.
21. Emori T, Hirata Y, Imai T, Ohta K, Kanno K, Eguchi S, Marumo F. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cells. Biochem Pharmacol. 1992;44:2409-2411.
22. 2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor messenger RNA expression in cultured endothelium. J Cell Physiol. 1993;156:541-549.
23. Storck J, Kusters B, Zimmermann ER. The tethered ligand receptor is the responsible receptor for the thrombin induced release of von Willebrand factor from endothelial cells (HUVEC). Thromb Res. 1995;77:249-258.
24. Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem. 1994;269:13936-13941.
25. Malik AB, Fenton JW II. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost. 1992;18:193-199.
26. Garcia JGN. Molecular mechanisms of thrombin-induced human and bovine endothelial cell activation. J Lab Clin Med. 1992;120:513-519.
27. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong CZ, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75:1029-1038.
28. Nelken NA, Soifer SJ, O'Keefe J, Vu T-KH, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
29. Dechend R, Mo X, Schulz W, Gross M, Praus M, Dietz R, Gulba DC. Thrombin receptor and urokinase-type plasminogen activator are colocalized in vascular smooth muscle cells derived from human carotid atherosclerotic plaques. Fibrinolysis. 1996;10:41-45.
30. Herbert JM, Guy AF, Lamarche I, Mares AM, Savi P, Dol F. Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide. J Cell Physiol. 1997;170: 106-114.
31. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res. 1998; 82:980-987.
32. Connolly TM, Condra C, Feng D-M, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost. 1994;72:627-633.
33. Derian CK, Santulli RJ, Tomko KA, Haertlein BJ, Andrade-Gordon P. Species differences in platelet responses to thrombin and SFLLRN: receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases. Thromb Res. 1995;78:505-519.
34. Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade-Gordon P. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 1996;76:860-866.
35. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature (London). 1996;381:516-519.
36. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792-796.
37. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
38. Jackson CL. Animal models of restenosis. Trends Cardiovasc Med. 1994; 4:122-130.
39. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996;28: 1643-1651.
40. Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest. 1975;32:339-351.
41. Duhamel-Clerin E, Orvain C, Lanza F, Cazenave J-P, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases. MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1931-1938.
42. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature (London). 1997;386:502-506.
43. Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood. 1998;91:4152-4157.
44. Fingerle J, Johnson R, Clowes A, Majesky M, Reidy M. Role of platelet in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A. 1989;86:8412-8416.
45. Lebreton H, Topol E, Plow EF. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis. Cardiovasc Res. 1996;31:235-236.